Company Analysis
Sign in

Q32 Bio Inc. (QTTB)

Nasdaq: QTTB · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.7
◀ Past 4.5● Present 6.5▶ Future 5.7
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Q32 Bio Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 6 in 2024 and none in 2023
Applications published
29
2 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Biotechnology5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Homology Medicines, Inc. a former name
named as the applicant on its applications, in US
0 granted
26 published
Homology Medicines, Inc. a former name
US, as the owner printed on each patent
8 granted
0 published
Q32 Bio Inc. its own name
US, as the owner printed on each patent
3 granted
0 published
Q32 Bio Inc. its own name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jan 21, 202512,203,094Adeno-associated virus compositions for restoring PAH gene function and methods of use thereofBiotechnologyHomology Medicines, Inc.
Sep 3, 202412,076,420Adeno-associated virus compositions for restoring PAH gene function and methods of use thereofBiotechnologyHomology Medicines, Inc.
Aug 20, 202412,064,486Adeno-associated virus compositions for PAH gene transfer and methods of use thereofPharmaceuticalsHomology Medicines, Inc.
Apr 9, 202411,952,585Methods of treating phenylketonuriaBiotechnologyHomology Medicines, Inc.
Apr 9, 202411,951,183Adeno-associated virus compositions for PAH gene transfer and methods of use thereofPharmaceuticalsHomology Medicines, Inc.
Feb 6, 202411,891,619Adeno-associated virus compositions for restoring F8 gene function and methods of use thereofBiotechnologyHomology Medicines, Inc.
Jan 23, 202411,879,008Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulatorPharmaceuticalsQ32 Bio Inc.
Apr 19, 202211,306,329Adeno-associated virus compositions for restoring F8 gene function and methods of use thereofBiotechnologyHomology Medicines, Inc.
Jul 6, 202111,053,306Fusion protein constructs comprising anti-C3d antibody and factor HPharmaceuticalsQ32 Bio Inc.
Jul 6, 202111,053,305Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptidePharmaceuticalsQ32 Bio Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Mar 27, 20252025/0101465ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOFBiotechnologyHomology Medicines, Inc.
Mar 20, 20252025/0090691ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING PAH GENE FUNCTION AND METHODS OF USE THEREOFBiotechnologyHomology Medicines, Inc.
Sep 12, 20242024/0301043METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORPharmaceuticalsQ32 Bio Inc.
Dec 14, 20232023/0399657LIVER DE-TARGETED RECOMBINANT AAV CAPSID PROTEINSBiotechnologyHomology Medicines, Inc.
Nov 23, 20232023/0374546BIDIRECTIONAL DUAL PROMOTER EXPRESSION VECTORS AND USES THEREOFPharmaceuticalsHomology Medicines, Inc.
Oct 12, 20232023/0323395METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUSBiotechnologyHomology Medicines, Inc.
Jun 15, 20232023/0183659METHODS AND COMPOSITIONS FOR THE PURIFICATION OF ADENO-ASSOCIATED VIRUSBiotechnologyHomology Medicines, Inc.
Apr 13, 20232023/0112648NON-NATURALLY OCCURRING POLYADENYLATION ELEMENTS AND METHODS OF USE THEREOFBiotechnologyHomology Medicines, Inc.
Mar 23, 20232023/0090654ADENO-ASSOCIATED VIRUS FORMULATIONSPharmaceuticalsHomology Medicines, Inc.
Feb 9, 20232023/0045171ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOFBiotechnologyHomology Medicines, Inc.
What it applied for, 2024 to 2025: Biotechnology 2 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton QTTB · research, not advice